A portion of this data was presented at the 17th Conference on Retroviruses and Opportunistic Infections (Abstract Q-170), February 2010 in San Francisco, CA.
HBV lamivudine resistance among hepatitis B and HIV coinfected patients starting lamivudine, stavudine and nevirapine in Kenya
Article first published online: 13 MAY 2011
© 2011 Blackwell Publishing Ltd
Journal of Viral Hepatitis
Volume 18, Issue 10, pages e447–e452, October 2011
How to Cite
Kim, H. N., Scott, J., Cent, A., Cook, L., Morrow, R. A., Richardson, B., Tapia, K., Jerome, K. R., Lule, G., John-Stewart, G. and Chung, M. H. (2011), HBV lamivudine resistance among hepatitis B and HIV coinfected patients starting lamivudine, stavudine and nevirapine in Kenya. Journal of Viral Hepatitis, 18: e447–e452. doi: 10.1111/j.1365-2893.2011.01466.x
- Issue published online: 14 SEP 2011
- Article first published online: 13 MAY 2011
- Received January 2011; accepted for publication March 2011
- hepatitis B virus;
- lamivudine resistance
Summary. Widespread use of lamivudine in antiretroviral therapy may lead to hepatitis B virus resistance in HIV–HBV coinfected patients from endemic settings where tenofovir is not readily available. We evaluated 389 Kenyan HIV-infected adults before and for 18 months after starting highly active antiretroviral therapy with stavudine, lamivudine and nevirapine. Twenty-seven (6.9%) were HBsAg positive and anti-HBs negative, 24 were HBeAg negative, and 18 had HBV DNA levels ≤10 000 IU/mL. Sustained HBV suppression to <100 IU/mL occurred in 89% of 19 evaluable patients. Resistance occurred in only two subjects, both with high baseline HBV DNA levels. Lamivudine resistance can emerge in the setting of incomplete HBV suppression but was infrequently observed among HIV–HBV coinfected patients with low baseline HBV DNA levels.